URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Edward Messing

TitleProfessor
InstitutionSchool of Medicine and Dentistry
DepartmentUrology
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 656
Rochester NY 14642
Other Positions
TitleChair
InstitutionSchool of Medicine and Dentistry
DepartmentUrology

TitleProfessor
InstitutionSchool of Medicine and Dentistry
DepartmentPathology and Laboratory Medicine

TitleProfessor
InstitutionUniversity of Rochester Medical Center
DepartmentCancer Center

 
 Awards And Honors
1968     Phil Beta Kappa
1972     Alpha Omega Alpha
1972     The Samuel Soifer Memorial Award for Outstanding Work in Urology - 1972
1975     Second Prize for Case Reports (Renal Arteriovenous Fistulas)
1977     First Prize for Clinical Research and the Bill Smart Award for Best Clinical Paper (Interstitial Cystitis)
1984 - 1986Junior Faculty Clinical Fellow  | American Cancer Society
1985     Sigma Xi  | The Scientific Research Society
1986     Fellow
1999     CaP Cure Award
2009     Davey Award  | James P. WIlmot Cancer Center
2010     2010 Best of Posters Award  | American Urological Association
2013     Presidential Citation Award  | American Urological Association
 
 Overview
Dr. Messing is an internationally renowned expert in all facets of urologic oncology, both as a clinician/surgeon, and as a clinical, translational and basic researcher.

His research contributions have ranged from enhancing our knowledge about the basic molecular biology and genetics of development and progression of cancers of the bladder, prostate and kidney, and bringing these studies to fruition for the detection, prevention and treatment of these diseases. He has also designed and conducted landmark phase III clinical trials for each of these cancers and has carried out the first
screening trial for bladder cancer in a general population. Important work has included defining the roles of epidermal growth factor (EGF) and its cell surface receptor in urothelial carcinogenesis and progression, investigating polyamine synthesis inhibition as a means to prevent bladder and prostate cancers, in large phase III clinical trials studying DFMO's ability to prevent bladder cancer's recurrence, the timing of androgen deprivation therapy (ADT) in treating regionally advanced completely resected prostate cancer, and the effectiveness of adjuvant alpha interferon for completely resected,
locally extensive, renal cell carcinoma. He has also contributed importantly to trials testing various forms of intravesical therapy for high risk, non-muscle invading bladder cancer, and the value of radiation therapy after prostatectomy for stage pT3 prostate cancer. He has demonstrated the feasibility of screening for bladder cancer (using hematuria reagent strips) and has worked on the development and testing of several molecular markers for the detection of bladder cancer.

Much of the above mentioned work continues, but currently he is also investigating gender disparities in bladder cancer's incidence and outcome. These efforts have ranged from investigations using large, national data bases, to molecular studies in cells and transgenic animal models. Additionally, he along with his basic science collaborators are investigating the preventative and therapeutic roles of nuclear transcription factors, vitamins and related molecules in prevention and treatment of prostate and bladder cancer. Furthermore, his clinical trial work
continues as the study coordinator (PI) of a large phase III clinical trial of immediate post TURBT intravesical instillation therapy for prevention of recurrence of low risk bladder cancer.

 
 Selected Publications
List All   |   Timeline
  1. Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res. 2014 May; 34(5):2405-11.
    View in: PubMed
  2. Dunne RF, Sahasrabudhe DM, Messing EM, Jean-Gilles J, Fung C. A case series of transformation of teratoma to primitive neuroectodermal tumor: evolving management of a rare malignancy. Rare Tumors. 2014 Jan 23; 6(1):5268.
    View in: PubMed
  3. Zhang H, Messing EM, Travis LB, Hyrien O, Chen R, Milano MT, Chen Y. Age and Racial Differences among PSA-Detected (AJCC Stage?T1cN0M0) Prostate Cancer in the U.S.: A Population-Based Study of 70,345 Men. Front Oncol. 2013; 3:312.
    View in: PubMed
  4. Hsu JW, Yin PN, Wood R, Messing J, Messing E, Lee YF. 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer. Oncotarget. 2013 Dec; 4(12):2397-406.
    View in: PubMed
  5. Scosyrev E, Messing E, Campbell S. Radical versus partial nephrectomy for a small renal mass: does saving nephrons save lives? Expert Rev Anticancer Ther. 2013 Dec; 13(12):1349-51.
    View in: PubMed
  6. Dogra VS, Chinni BK, Valluru KS, Joseph JV, Ghazi A, Yao JL, Evans K, Messing EM, Rao NA. Multispectral Photoacoustic Imaging of Prostate Cancer: Preliminary Ex-vivo Results. J Clin Imaging Sci. 2013; 3:41.
    View in: PubMed
  7. Donsky H, Coyle S, Scosyrev E, Messing EM. Sex differences in incidence and mortality of bladder and kidney cancers: National estimates from 49 countries. Urol Oncol. 2014 Jan; 32(1):40.e23-31.
    View in: PubMed
  8. Scosyrev E, Messing EM, Sylvester R, Campbell S, Van Poppel H. Renal Function After Nephron-sparing Surgery Versus Radical Nephrectomy: Results from EORTC Randomized Trial 30904. Eur Urol. 2014 Feb; 65(2):372-7.
    View in: PubMed
  9. Messing EM. N+, M0 prostate cancer: local therapy for systemic disease. Oncology (Williston Park). 2013 Jul; 27(7):661-2, 668.
    View in: PubMed
  10. Borch M, Scosyrev E, Baron B, Encarnacion J, Smith EM, Messing E. A randomized trial of 2% lidocaine gel versus plain lubricating gel for minimizing pain in men undergoing flexible cystoscopy. Urol Nurs. 2013 Jul-Aug; 33(4):187-93.
    View in: PubMed
  11. Yang DR, Lin SJ, Ding XF, Miyamoto H, Messing E, Li LQ, Wang N, Chang C. Higher Expression of Peroxisome Proliferator-activated Receptor ? or Its Activation by Agonist Thiazolidinedione-rosiglitazone Promotes Bladder Cancer Cell Migration and Invasion. Urology. 2013 May; 81(5):1109.e1-6.
    View in: PubMed
  12. Ghazi A, Scosyrev E, Patel H, Messing EM, Joseph JV. Complications Associated With Extraperitoneal Robot-assisted Radical Prostatectomy Using the Standardized Martin Classification. Urology. 2013 Feb; 81(2):324-33.
    View in: PubMed
  13. Weight CJ, Miller DC, Campbell SC, Derweesh IH, Lane BR, Messing EM. The management of a clinical t1b renal tumor in the presence of a normal contralateral kidney. J Urol. 2013 Apr; 189(4):1198-202.
    View in: PubMed
  14. Larré S, Catto JW, Cookson MS, Messing EM, Shariat SF, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol. 2013 Jun; 63(6):1049-58.
    View in: PubMed
  15. Messing EM. Words of wisdom. Re: Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Eur Urol. 2012 Nov; 62(5):935-6.
    View in: PubMed
  16. Davis R, Jones JS, Barocas DA, Castle EP, Lang EK, Leveillee RJ, Messing EM, Miller SD, Peterson AC, Turk TM, Weitzel W. Diagnosis, Evaluation and Follow-Up of Asymptomatic Microhematuria (AMH) in Adults: AUA Guideline. J Urol. 2012 Dec; 188(6 Suppl):2473-81.
    View in: PubMed
  17. Scosyrev E, Messing EM. Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : Analysis of Trends Over Time. Cancer. 2013 Mar 1; 119(5):1113-4.
    View in: PubMed
  18. Baran TM, Wilson JD, Mitra S, Yao JL, Messing EM, Waldman DL, Foster TH. Optical property measurements establish the feasibility of photodynamic therapy as a minimally invasive intervention for tumors of the kidney. J Biomed Opt. 2012 Sep 28; 17(9):98002-1.
    View in: PubMed
  19. Scosyrev E, Tobis S, Donsky H, Wu G, Joseph J, Rashid H, Messing E. Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies. BJU Int. 2013 Mar; 111(3 Pt B):E71-7.
    View in: PubMed
  20. Byler TK, Leocadio D, Shapiro O, Bratslavsky G, Stodgell CJ, Wood RW, Messing EM, Reeder JE. Valproic acid decreases urothelial cancer cell proliferation and induces thrombospondin-1 expression. BMC Urol. 2012; 12:21.
    View in: PubMed
  21. Shyr CR, Chen CC, Hsieh TF, Chang CH, Ma WL, Yeh S, Messing E, Li TH, Li FY, Chang C. The expression and actions of androgen receptor in upper urinary tract urothelial carcinoma (UUTUC) tissues and the primary cultured cells. Endocrine. 2013 Feb; 43(1):191-9.
    View in: PubMed
  22. Scosyrev E, Wu G, Mohile S, Messing EM. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : Analysis of trends over time. Cancer. 2012 Dec 1; 118(23):5768-76.
    View in: PubMed
  23. Scosyrev E, Wu G, Golijanin D, Messing E. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system. BJU Int. 2012 Nov; 110(10):1485-90.
    View in: PubMed
  24. Messing EM. Editorial comment. J Urol. 2012 May; 187(5):1564-5; discussion 1565.
    View in: PubMed
  25. Tobis S, Knopf JK, Silvers C, Messing E, Yao J, Rashid H, Wu G, Golijanin D. Robot-assisted and laparoscopic partial nephrectomy with near infrared fluorescence imaging. J Endourol. 2012 Jul; 26(7):797-802.
    View in: PubMed
  26. Tobis S, Knopf JK, Silvers CR, Marshall J, Cardin A, Wood RW, Reeder JE, Erturk E, Madeb R, Yao J, Singer EA, Rashid H, Wu G, Messing E, Golijanin D. Near infrared fluorescence imaging after intravenous indocyanine green: initial clinical experience with open partial nephrectomy for renal cortical tumors. Urology. 2012 Apr; 79(4):958-64.
    View in: PubMed
  27. Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila). 2012 Apr; 5(4):621-30.
    View in: PubMed
  28. Miyamoto H, Yao JL, Chaux A, Zheng Y, Hsu I, Izumi K, Chang C, Messing EM, Netto GJ, Yeh S. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012 Jun; 109(11):1716-26.
    View in: PubMed
  29. Messing EM, Albertsen P, Andriole GL, Carroll PR, Klein EA. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. Urol Oncol. 2012 Jan-Feb; 30(1):117-9.
    View in: PubMed
  30. Knopf J, Messing E. Editorial comment. Urology. 2012 Jan; 79(1):171.
    View in: PubMed
  31. Ting HJ, Yasmin-Karim S, Yan SJ, Hsu JW, Lin TH, Zeng W, Messing J, Sheu TJ, Bao BY, Li WX, Messing E, Lee YF. A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res. 2012 Feb 15; 72(4):958-68.
    View in: PubMed
  32. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012 Jun 15; 118(12):3062-70.
    View in: PubMed
  33. Lloyd GL, Singh MJ, Messing EM. An unusual cause of an enhancing retroperitoneal mass. Urology. 2012 Apr; 79(4):e61-2.
    View in: PubMed
  34. Gordetsky J, Scosyrev E, Rashid H, Wu G, Silvers C, Golijanin D, Messing EM, Yao JL. Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimens. Mod Pathol. 2012 Jan; 25(1):140-4.
    View in: PubMed
  35. Scosyrev E, Messing EM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? BJU Int. 2011 Sep; 108(5):700.
    View in: PubMed
  36. Scosyrev E, Golijanin D, Wu G, Messing E. The burden of bladder cancer in men and women: analysis of the years of life lost. BJU Int. 2012 Jan; 109(1):57-62.
    View in: PubMed
  37. Gordetsky J, Findeis-Hosey J, Erturk E, Messing EM, Yao JL, Miyamoto H. Role of frozen section analysis of testicular/paratesticular fibrous pseudotumours: a five-case experience. Can Urol Assoc J. 2011 Aug; 5(4):E47-51.
    View in: PubMed
  38. Scosyrev E, Messing EM, van Wijngaarden E, Peterson DR, Sahasrabudhe D, Golijanin D, Fisher SG. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer. 2012 Jan 1; 118(1):72-81.
    View in: PubMed
  39. Scosyrev E, Wu G, Golijanin D, Messing E. Non-bladder cancer mortality in patients with urothelial cancer of the bladder. Urol Oncol. 2013 Jul; 31(5):656-63.
    View in: PubMed
  40. Messing E. Words of Wisdom. Re: potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2011 Feb; 59(2):302-3.
    View in: PubMed
  41. Loberant N, Bhatt S, Messing E, Dogra VS. Bilateral testicular epidermoid cysts. J Clin Imaging Sci. 2011; 1:4.
    View in: PubMed
  42. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2011 Sep; 108(5):693-9.
    View in: PubMed
  43. Mir C, Shariat SF, van der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int. 2011 Jul; 108(1):24-30.
    View in: PubMed
  44. He X, Wang J, Messing EM, Wu G. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness. Oncogene. 2011 Feb 3; 30(5):535-47.
    View in: PubMed
  45. Scosyrev E, Trivedi D, Messing E. Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol. 2010 Sep; 20(5):404-8.
    View in: PubMed
  46. Scosyrev E, Yao J, Messing E. Microscopic invasion of perivesical fat by urothelial carcinoma: implications for prognosis and pathology practice. Urology. 2010 Oct; 76(4):908-13; discussion 914.
    View in: PubMed
  47. Messing EM, Golijanin D, Knopf J, Madeb R. Re: Dipstick pseudohematuria: unnecessary consultation and evaluation. P. K. Rao, T. Gao, M. Pohl and J. S. Jones J Urol 2010; 183: 560-565. J Urol. 2010 Sep; 184(3):1225; author reply 1225-6.
    View in: PubMed
  48. Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol. 2010 May-Jun; 28(3):338-42.
    View in: PubMed
  49. Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y. BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. Urol Oncol. 2010 May-Jun; 28(3):334-7.
    View in: PubMed
  50. Purnell JQ, Palesh OG, Heckler CE, Adams MJ, Chin N, Mohile S, Peppone LJ, Atkins JN, Moore DF, Spiegel D, Messing E, Morrow GR. Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men. Support Care Cancer. 2011 Jul; 19(7):899-907.
    View in: PubMed
  51. Bendaña EE, Trivedi D, Marshall J, Messing E. Lost and now found: retained straight catheter for 20 years. Urology. 2011 Jan; 77(1):73-4.
    View in: PubMed
  52. Scosyrev E, Messing J, Noyes K, Veazie P, Messing E. Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview. Urol Oncol. 2012 Mar-Apr; 30(2):126-32.
    View in: PubMed
  53. Bao BY, Ting HJ, Hsu JW, Yasmin-Karim S, Messing E, Lee YF. Down-regulation of NF-kappaB signals is involved in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. J Steroid Biochem Mol Biol. 2010 May; 120(1):11-21.
    View in: PubMed
  54. Palapattu GS, Singer EA, Messing EM. Controversies surrounding lymph node dissection for prostate cancer. Urol Clin North Am. 2010 Feb; 37(1):57-65, Table of Contents.
    View in: PubMed
  55. Kohli M, Rothberg PG, Feng C, Messing E, Joseph J, Rao SS, Hendershot A, Sahsrabudhe D. Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer. Cancer Biomark. 2010; 7(2):101-8.
    View in: PubMed
  56. Madeb R, Golijanin D, Knopf J, Davis M, Feng C, Fender A, Stephenson L, Messing EM. Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology. 2010 Jan; 75(1):20-5.
    View in: PubMed
  57. Trivedi D, Messing EM. Commentary: the role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria. BMC Urol. 2009; 9:13.
    View in: PubMed
  58. Messing E. Words of wisdom. Re: Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. Kramer BS, Hagerty KL, Justman S, et al. Eur Urol. 2009 Sep; 56(3):572.
    View in: PubMed
  59. Yan K, Podder T, Li L, Joseph J, Rubens DR, Messing EM, Liao L, Yu Y. A real-time prostate cancer detection technique using needle insertion force and patient-specific criteria during percutaneous intervention. Med Phys. 2009 Sep; 36(9):4184-90.
    View in: PubMed
  60. Yan K, Li L, Joseph J, Rubens DR, Messing EM, Liao L, Yu Y. A real-time prostate cancer detection technique using needle insertion force and patient-specific criteria during percutaneous intervention. Med Phys. 2009 Jul; 36(7):3356-62.
    View in: PubMed
  61. Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, Knopf J, Lyman GH, Messing EM. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009 Jun 15; 115(12):2660-70.
    View in: PubMed
  62. Messing EM, Madeb R, Feng C, Stephenson L, Gilchrist KW, Young T, Gee J. Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease. J Clin Oncol. 2009 May 20; 27(15):2443-9.
    View in: PubMed
  63. Scosyrev E, Yao J, Messing E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology. 2009 Apr; 73(4):822-7.
    View in: PubMed
  64. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009 Mar; 181(3):956-62.
    View in: PubMed
  65. Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009 Jan 1; 115(1):68-74.
    View in: PubMed
  66. Singer EA, Golijanin DJ, Messing EM. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged? Can J Urol. 2008 Dec; 15(6):4381-7.
    View in: PubMed
  67. Gee JR, Jarrard DF, Bruskewitz RC, Moon TD, Hedican SP, Leverson GE, Nakada SY, Messing EM. Reduced bladder cancer recurrence rate with cardioprotective aspirin after intravesical bacille Calmette-Guérin. BJU Int. 2009 Mar; 103(6):736-9.
    View in: PubMed
  68. Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol. 2008 Dec; 180(6):2453-7; discussion 2458.
    View in: PubMed
  69. Noyes K, Singer EA, Messing EM. Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors. Curr Opin Urol. 2008 Sep; 18(5):533-9.
    View in: PubMed
  70. Chen M, Hsu I, Wolfe A, Radovick S, Huang K, Yu S, Chang C, Messing EM, Yeh S. Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice. Endocrinology. 2009 Jan; 150(1):251-9.
    View in: PubMed
  71. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A. 2008 Aug 26; 105(34):12182-7.
    View in: PubMed
  72. Ignatoff JM, Chen YH, Greenberg RE, Pow-Sang JM, Messing EM, Wilding G. Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group. Urol Oncol. 2009 Sep-Oct; 27(5):496-501.
    View in: PubMed
  73. Johnson AM, O'Connell MJ, Messing EM, Reeder JE. Decreased bladder cancer growth in parous mice. Urology. 2008 Sep; 72(3):470-3.
    View in: PubMed
  74. Johnson AM, O'Connell MJ, Miyamoto H, Huang J, Yao JL, Messing EM, Reeder JE. Androgenic dependence of exophytic tumor growth in a transgenic mouse model of bladder cancer: a role for thrombospondin-1. BMC Urol. 2008; 8:7.
    View in: PubMed
  75. Messing EM. Why should we increase public awareness of bladder cancer, and how can we do it? Nat Clin Pract Urol. 2008 Mar; 5(3):117.
    View in: PubMed
  76. Podder T, Sherman J, Rubens D, Messing E, Strang J, Ng WS, Yu Y. Methods for prostate stabilization during transperineal LDR brachytherapy. Phys Med Biol. 2008 Mar 21; 53(6):1563-79.
    View in: PubMed
  77. Zhang M, Nigwekar P, Castaneda B, Hoyt K, Joseph JV, di Sant'Agnese A, Messing EM, Strang JG, Rubens DJ, Parker KJ. Quantitative characterization of viscoelastic properties of human prostate correlated with histology. Ultrasound Med Biol. 2008 Jul; 34(7):1033-42.
    View in: PubMed
  78. Singer EA, Golijanin DJ, Miyamoto H, Messing EM. Androgen deprivation therapy for prostate cancer. Expert Opin Pharmacother. 2008 Feb; 9(2):211-28.
    View in: PubMed
  79. Madeb R, Messing EM. Long-term outcome of home dipstick testing for hematuria. World J Urol. 2008 Feb; 26(1):19-24.
    View in: PubMed
  80. Yu Y, Podder TK, Zhang YD, Ng WS, Misic V, Sherman J, Fuller D, Rubens DJ, Strang JG, Brasacchio RA, Messing EM. Robotic system for prostate brachytherapy. Comput Aided Surg. 2007 Nov; 12(6):366-70.
    View in: PubMed
  81. Hutson PR, Oettel K, Douglas J, Ritter M, Messing E, Staab MJ, Alberti D, Horvath D, Wilding G. Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemother Pharmacol. 2008 Aug; 62(3):373-7.
    View in: PubMed
  82. Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Mol Cancer Res. 2007 Sep; 5(9):967-80.
    View in: PubMed
  83. Messing E. Markers of detection. Urol Oncol. 2007 Jul-Aug; 25(4):344-7.
    View in: PubMed
  84. Madeb R, Golijanin D, Knopf J, Messing EM. Current state of screening for bladder cancer. Expert Rev Anticancer Ther. 2007 Jul; 7(7):981-7.
    View in: PubMed
  85. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford ED. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol. 2007 Jun 1; 25(16):2225-9.
    View in: PubMed
  86. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst. 2007 Apr 4; 99(7):558-68.
    View in: PubMed
  87. Messing EM. Re: Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Eur Urol. 2007 Apr; 51(4):1140.
    View in: PubMed
  88. Messing EM. Node positive renal cell cancer. Who can be helped? Eur Urol. 2007 Jun; 51(6):1477-8.
    View in: PubMed
  89. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33.
    View in: PubMed
  90. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15; 296(19):2329-35.
    View in: PubMed
  91. Golijanin DJ, Kakiashvili D, Madeb RR, Messing EM, Lerner SP. Chemoprevention of bladder cancer. World J Urol. 2006 Nov; 24(5):445-72.
    View in: PubMed
  92. Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB, Wegenke JD, Stephenson L, Gee J, Feng C. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006 Nov 1; 107(9):2173-9.
    View in: PubMed
  93. Boczko J, Messing E, Dogra V. Transrectal sonography in prostate evaluation. Radiol Clin North Am. 2006 Sep; 44(5):679-87, viii.
    View in: PubMed
  94. Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol. 2006 Aug; 176(2):500-4.
    View in: PubMed
  95. Podder T, Clark D, Sherman J, Fuller D, Messing E, Rubens D, Strang J, Brasacchio R, Liao L, Ng WS, Yu Y. Vivo motion and force measurement of surgical needle intervention during prostate brachytherapy. Med Phys. 2006 Aug; 33(8):2915-22.
    View in: PubMed
  96. Wood RW, Baggs RB, Schwarz EM, Messing EM. Initial observations of reduced uroflow in transgenic adenocarcinoma of murine prostate. Urology. 2006 Jun; 67(6):1324-8.
    View in: PubMed
  97. Johnson AM, Conover DL, Huang J, Messing EM, Ning R, O'Connell MJ, Rossi MA, Sun TT, Wood RW, Wu XR, Reeder JE. Early detection and measurement of urothelial tumors in mice. Urology. 2006 Jun; 67(6):1309-14.
    View in: PubMed
  98. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di'SantAgnese PA, Trump D. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006 Jun; 7(6):472-9.
    View in: PubMed
  99. Fu L, Liu H, Ng WS, Rubens D, Strang J, Messing E, Yu Y. Hybrid dosimetry: feasibility of mixing angulated and parallel needles in planning prostate brachytherapy. Med Phys. 2006 May; 33(5):1192-8.
    View in: PubMed
  100. Palapattu GS, Messing EM. Do prostate cancer patients at risk of pelvic lymph-node metastasis benefit from pelvic radiation? Nat Clin Pract Urol. 2006 May; 3(5):258-9.
    View in: PubMed
  101. Messing EM. Bladder tumor markers. J Urol. 2006 Apr; 175(4):1195-6.
    View in: PubMed
  102. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006 Jan 18; 295(3):299-305.
    View in: PubMed
  103. Podder TK, Sherman J, Messing EM, Rubens DJ, Fuller D, Strang JG, Brasacchio RA, Yu Y. Needle insertion force estimation model using procedure-specific and patient-specific criteria. Conf Proc IEEE Eng Med Biol Soc. 2006; 1:555-8.
    View in: PubMed
  104. Podder TK, Sherman J, Fuller D, Messing EM, Rubens DJ, Strang JG, Brasacchio RA, Yu Y. In-vivo measurement of surgical needle intervention parameters: a pilot study. Conf Proc IEEE Eng Med Biol Soc. 2006; 1:3652-5.
    View in: PubMed
  105. Yu Y, Podder T, Zhang Y, Ng WS, Misic V, Sherman J, Fu L, Fuller D, Messing E, Rubens D, Strang J, Brasacchio R. Robot-assisted prostate brachytherapy. Med Image Comput Comput Assist Interv. 2006; 9(Pt 1):41-9.
    View in: PubMed
  106. Sherman J, Podder TK, Misic V, Fu L, Fuller D, Winey B, Messing EM, Rubens DJ, Strang JG, Brasacchio R, Yu Y. Efficacy of prostate stabilizing techniques during brachytherapy procedure. Conf Proc IEEE Eng Med Biol Soc. 2006; 1:563-6.
    View in: PubMed
  107. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology. 2005 Dec; 66(6 Suppl 1):35-63.
    View in: PubMed
  108. Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005 Dec; 66(6 Suppl 1):64-74.
    View in: PubMed
  109. Ni J, Wen X, Yao J, Chang HC, Yin Y, Zhang M, Xie S, Chen M, Simons B, Chang P, di Sant'Agnese A, Messing EM, Yeh S. Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Res. 2005 Nov 1; 65(21):9807-16.
    View in: PubMed
  110. Taylor LS, Rubens DJ, Porter BC, Wu Z, Baggs RB, di Sant'Agnese PA, Nadasdy G, Pasternack D, Messing EM, Nigwekar P, Parker KJ. Prostate cancer: three-dimensional sonoelastography for in vitro detection. Radiology. 2005 Dec; 237(3):981-5.
    View in: PubMed
  111. Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B, Qian J, Bostwick DG. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol. 2005 Oct; 174(4 Pt 1):1238-41.
    View in: PubMed
  112. Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog. 2005 Sep; 44(1):1-10.
    View in: PubMed
  113. Miyamoto H, Messing EM, Chang C. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nat Clin Pract Oncol. 2005 May; 2(5):236-7.
    View in: PubMed
  114. Li Z, Wang D, Messing EM, Wu G. VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep. 2005 Apr; 6(4):373-8.
    View in: PubMed
  115. Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, Culkin DJ, Diokno A, Hanno P, Landis JR, Madigan R, Messing EM, Nickel JC, Sant GR, Warren J, Wein AJ, Kusek JW, Nyberg LM, Foster HE. A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol. 2005 Apr; 173(4):1186-91.
    View in: PubMed
  116. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, Shen Y. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005 Feb 16; 293(7):810-6.
    View in: PubMed
  117. Wang D, Li Z, Messing EM, Wu G. The SPRY domain-containing SOCS box protein 1 (SSB-1) interacts with MET and enhances the hepatocyte growth factor-induced Erk-Elk-1-serum response element pathway. J Biol Chem. 2005 Apr 22; 280(16):16393-401.
    View in: PubMed
  118. Fu L, Ng WS, Liu H, O'Dell W, Rubens D, Strang J, Schell MC, Brasacchio R, Liao L, Messing E, Yu Y. Bouquet brachytherapy: feasibility and optimization of conically spaced implants. Brachytherapy. 2005; 4(1):59-63.
    View in: PubMed
  119. Podder TK, Clark DP, Fuller D, Sherman J, Ng WS, Liao L, Rubens DJ, Strang JG, Messing EM, Zhang YD, Yu Y. Effects of velocity modulation during surgical needle insertion. Conf Proc IEEE Eng Med Biol Soc. 2005; 6:5766-70.
    View in: PubMed
  120. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate. 2004 Dec 1; 61(4):332-53.
    View in: PubMed
  121. Leung YY, Schwarz EM, Silvers CR, Messing EM, Wood RW. Uroflow in murine urethritis. Urology. 2004 Aug; 64(2):378-82.
    View in: PubMed
  122. Rashid HH, Cos LR, Weinberg E, Messing EM. Testicular microlithiasis: a review and its association with testicular cancer. Urol Oncol. 2004 Jul-Aug; 22(4):285-9.
    View in: PubMed
  123. Miyamoto H, Messing EM. Early versus late hormonal therapy for prostate cancer. Curr Urol Rep. 2004 Jun; 5(3):188-96.
    View in: PubMed
  124. Rashid HH, Reeder JE, O'Connell MJ, Zhang CO, Messing EM, Keay SK. Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulator. BMC Urol. 2004 Apr 6; 4:3.
    View in: PubMed
  125. Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol. 2004 Mar-Apr; 22(2):86-92.
    View in: PubMed
  126. Wang D, Li Z, Schoen SR, Messing EM, Wu G. A novel MET-interacting protein shares high sequence similarity with RanBPM, but fails to stimulate MET-induced Ras/Erk signaling. Biochem Biophys Res Commun. 2004 Jan 9; 313(2):320-6.
    View in: PubMed
  127. Wright KO, Messing EM, Reeder JE. DBCCR1 mediates death in cultured bladder tumor cells. Oncogene. 2004 Jan 8; 23(1):82-90.
    View in: PubMed
  128. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004 Jan 1; 58(1):3-10.
    View in: PubMed
  129. Messing EM. Re: Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol. 2003 Nov; 170(5):1955; author reply 1955-6.
    View in: PubMed
  130. Messing EM, Thompson I. Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Urol Clin North Am. 2003 Nov; 30(4):687-702, viii.
    View in: PubMed
  131. Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol. 2003 Sep; 170(3):810-5.
    View in: PubMed
  132. Na X, Duan HO, Messing EM, Schoen SR, Ryan CK, di Sant'Agnese PA, Golemis EA, Wu G. Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein. EMBO J. 2003 Aug 15; 22(16):4249-59.
    View in: PubMed
  133. Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol. 2003 Aug; 170(2 Pt 1):588-92.
    View in: PubMed
  134. Messing E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol Oncol. 2003 Jul-Aug; 21(4):245-54.
    View in: PubMed
  135. Borhan A, Reeder JE, O'Connell MJ, Wright KO, Wheeless LL, di Sant'Agnese PA, McNally ML, Messing EM. Grade progression and regression in recurrent urothelial cancer. J Urol. 2003 Jun; 169(6):2106-9.
    View in: PubMed
  136. Liu H, Cheng G, Yu Y, Brasacchio R, Rubens D, Strang J, Liao L, Messing E. Automatic localization of implanted seeds from post-implant CT images. Phys Med Biol. 2003 May 7; 48(9):1191-203.
    View in: PubMed
  137. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J. 2003 Apr 15; 22(8):1857-67.
    View in: PubMed
  138. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, Pontes JE, Hahn R, Trump D. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003 Apr 1; 21(7):1214-22.
    View in: PubMed
  139. Wright KO, Messing EM, Reeder JE. Increased expression of the acid sphingomyelinase-like protein ASML3a in bladder tumors. J Urol. 2002 Dec; 168(6):2645-9.
    View in: PubMed
  140. Gottlieb RH, La TC, Erturk EN, Sotack JL, Voci SL, Holloway RG, Syed L, Mikityansky I, Tirkes AT, Elmarzouky R, Zwemer FL, Joseph JV, Davis D, DiGrazio WJ, Messing EM. CT in detecting urinary tract calculi: influence on patient imaging and clinical outcomes. Radiology. 2002 Nov; 225(2):441-9.
    View in: PubMed
  141. Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res. 2002 Nov 1; 62(21):6039-44.
    View in: PubMed
  142. Sessions A, Eichel L, Kassahun M, Messing EM, Schwarz E, Wood RW. Continuous bladder infusion methods for studying voiding function in the ambulatory mouse. Urology. 2002 Oct; 60(4):707-13.
    View in: PubMed
  143. Wang D, Li Z, Messing EM, Wu G. Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem. 2002 Sep 27; 277(39):36216-22.
    View in: PubMed
  144. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochem Biophys Res Commun. 2002 Jun 14; 294(3):700-9.
    View in: PubMed
  145. Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A. 2002 May 28; 99(11):7408-13.
    View in: PubMed
  146. Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. Prostate. 2002 May 15; 51(3):153-65.
    View in: PubMed
  147. Sessions AE, Messing EM. Timing hormonal therapy in prostate cancer. Urol Clin North Am. 2002 Feb; 29(1):223-7, xi.
    View in: PubMed
  148. Li Z, Na X, Wang D, Schoen SR, Messing EM, Wu G. Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2002 Feb 15; 277(7):4656-62.
    View in: PubMed
  149. Brawer MK, Stamey TA, Fowler J, Droller M, Messing E, Fair WR. Perspectives on prostate cancer diagnosis and treatment: a roundtable. Urology. 2001 Aug; 58(2):135-40.
    View in: PubMed
  150. Eichel L, Scheidweiler K, Kost J, Shojaie J, Schwarz E, Messing E, Wood R. Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine. Urology. 2001 Jul; 58(1):113-8.
    View in: PubMed
  151. Eichel L, Scheidweiler K, Kost J, Shojaie J, Schwarz E, Messing EM, Wood R. Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine. Urology. 2001 Jun; 57(6 Suppl 1):115.
    View in: PubMed
  152. Wood R, Eichel L, Messing EM, Schwarz E. Automated noninvasive measurement of cyclophosphamide-induced changes in murine micturition frequency and volume and demonstration of pharmacologic sensitivity. Urology. 2001 Jun; 57(6 Suppl 1):115-6.
    View in: PubMed
  153. Eichel LS, Sessions AE, Messing EM, Schwarz E, Wood RW. Continuous bladder infusion methods for studying voiding function in ambulatory mice. Urology. 2001 Jun; 57(6 Suppl 1):115.
    View in: PubMed
  154. Wood R, Pittelli R, Foster D, Mayer R, Messing EM. Human bladder permeability assessment using intravesical fluorescein clearance rate. Urology. 2001 Jun; 57(6 Suppl 1):131-2.
    View in: PubMed
  155. Strang JG, Rubens DJ, Brasacchio RA, Yu Y, Messing EM. Real-time US versus CT determination of pubic arch interference for brachytherapy. Radiology. 2001 May; 219(2):387-93.
    View in: PubMed
  156. Mantalaris A, Panoskaltsis N, Sakai Y, Bourne P, Chang C, Messing EM, Wu JH. Localization of androgen receptor expression in human bone marrow. J Pathol. 2001 Mar; 193(3):361-6.
    View in: PubMed
  157. Wood R, Eichel L, Messing EM, Schwarz E. Automated noninvasive measurement of cyclophosphamide-induced changes in murine voiding frequency and volume. J Urol. 2001 Feb; 165(2):653-9.
    View in: PubMed
  158. Eichel L, Messing E. The timing of hormonal treatment for prostate cancer. Curr Opin Urol. 2000 Sep; 10(5):403-7.
    View in: PubMed
  159. Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control. 2000 Jul-Aug; 7(4):325-34.
    View in: PubMed
  160. deVere White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED. The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study. Eur Urol. 2000 May; 37(5):595-600.
    View in: PubMed
  161. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999 Dec 9; 341(24):1781-8.
    View in: PubMed
  162. Jung I, Reeder JE, Cox C, Siddiqui JF, O'Connell MJ, Collins L, Yang Z, Messing EM, Wheeless LL. Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. J Urol. 1999 Dec; 162(6):1900-3.
    View in: PubMed
  163. Messing EM, Love RR, Tutsch KD, Verma AK, Douglas J, Pomplun M, Simsiman R, Wilding G. Low-dose difluoromethylornithine and polyamine levels in human prostate tissue. J Natl Cancer Inst. 1999 Aug 18; 91(16):1416-7.
    View in: PubMed
  164. Messing EM, Zhang JB, Rubens DJ, Brasacchio RA, Strang JG, Soni A, Schell MC, Okunieff PG, Yu Y. Intraoperative optimized inverse planning for prostate brachytherapy: early experience. Int J Radiat Oncol Biol Phys. 1999 Jul 1; 44(4):801-8.
    View in: PubMed
  165. Gottlieb RH, Zusman E, Hartley DF, Rubens DJ, Voci SL, Robinette W, Melendez L, Morris TW, Ojha S, Chengazi V, Erturk E, Messing EM. Effect of angiotensin converting enzyme inhibition on the Doppler waveform in dogs with renal artery stenosis. J Ultrasound Med. 1999 Jul; 18(7):481-7.
    View in: PubMed
  166. Messing EM. Interstitial cystitis--a light at the end of the tunnel? J Urol. 1999 Jun; 161(6):1797.
    View in: PubMed
  167. Yu Y, Zhang JB, Brasacchio RA, Okunieff PG, Rubens DJ, Strang JG, Soni A, Messing EM. Automated treatment planning engine for prostate seed implant brachytherapy. Int J Radiat Oncol Biol Phys. 1999 Feb 1; 43(3):647-52.
    View in: PubMed
  168. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C. Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci U S A. 1998 Sep 15; 95(19):11083-8.
    View in: PubMed
  169. Pan HJ, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, Chang C. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine. 1998 Aug; 9(1):39-43.
    View in: PubMed
  170. Reeder JE, O'Connell MJ, Yang Z, Morreale JF, Collins L, Frank IN, Messing EM, Cockett AT, Cox C, Robinson RD, Wheeless LL. DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients. Urology. 1998 May; 51(5A Suppl):58-61.
    View in: PubMed
  171. Jepsen JV, Sall M, Rhodes PR, Schmidt D, Messing E, Bruskewitz RC. Long-term experience with pentosanpolysulfate in interstitial cystitis. Urology. 1998 Mar; 51(3):381-7.
    View in: PubMed
  172. Stewart J, Kozlowski P, Sowden M, Messing E, Smith HC. A quantitative assay for assessing allelic proportions by iterative gap ligation. Nucleic Acids Res. 1998 Feb 15; 26(4):961-6.
    View in: PubMed
  173. Goldstein MM, Messing EM. Prostate and bladder cancer screening. J Am Coll Surg. 1998 Jan; 186(1):63-74.
    View in: PubMed
  174. Reeder JE, Morreale JF, O'Connell MJ, Stadler WM, Olopade OF, Messing EM, Wheeless LL. Loss of the CDKN2A/p16 locus detected in bladder irrigation specimens by fluorescence in situ hybridization. J Urol. 1997 Nov; 158(5):1717-21.
    View in: PubMed
  175. Buzzeo BD, Heisey DM, Messing EM. Bladder cancer in renal transplant recipients. Urology. 1997 Oct; 50(4):525-8.
    View in: PubMed
  176. Foresman WH, Messing EM. Bladder cancer: natural history, tumor markers, and early detection strategies. Semin Surg Oncol. 1997 Sep-Oct; 13(5):299-306.
    View in: PubMed
  177. Messing E, Pauk D, Schaeffer A, Nieweglowski M, Nyberg LM, Landis JR, Cook YL, Simon LJ. Associations among cystoscopic findings and symptoms and physical examination findings in women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. Urology. 1997 May; 49(5A Suppl):81-5.
    View in: PubMed
  178. Sall M, Madsen FA, Rhodes PR, Jønler M, Messing EM, Bruskewitz RC. Pelvic pain following radical retropubic prostatectomy: a prospective study. Urology. 1997 Apr; 49(4):575-9.
    View in: PubMed
  179. Kryger JV, Messing E. Bladder cancer screening. Semin Oncol. 1996 Oct; 23(5):585-97.
    View in: PubMed
  180. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB, Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 1996 Oct; 156(4):1280-5.
    View in: PubMed
  181. Jønler M, Madsen FA, Rhodes PR, Sall M, Messing EM, Bruskewitz RC. A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Urology. 1996 Sep; 48(3):433-40.
    View in: PubMed
  182. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996 Aug; 156(2 Pt 1):363-7.
    View in: PubMed
  183. Loprinzi CL, Messing EM, O'Fallon JR, Poon MA, Love RR, Quella SK, Trump DL, Morton RF, Novotny P. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. Cancer Epidemiol Biomarkers Prev. 1996 May; 5(5):371-4.
    View in: PubMed
  184. Wu SQ, Hafez GR, Xing W, Newton M, Chen XR, Messing E. The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with nonpapillary renal cell carcinoma. Cancer. 1996 Mar 15; 77(6):1154-60.
    View in: PubMed
  185. Devere White RW, Deitch AD, Tesluk H, Blumensteinj B, Lowe BA, Sagalowsky AI, Smith JA, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED. Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study. Urol Oncol. 1996 Jan-Feb; 2(1):27-34.
    View in: PubMed
  186. D'Alessandro AM, Sollinger HW, Knechtle SJ, Kalayoglu M, Kisken WA, Uehling DT, Moon TD, Messing EM, Bruskewitz RC, Pirsch JD, et al. Living related and unrelated donors for kidney transplantation. A 28-year experience. Ann Surg. 1995 Sep; 222(3):353-62; discussion 362-4.
    View in: PubMed
  187. Howard SP, Groch KM, Lindstrom MJ, Messing EM, Gould MN. Proliferation-independent growth factor modulation of the radiation sensitivity of human prostate cells. Radiat Res. 1995 Aug; 143(2):229-33.
    View in: PubMed
  188. Messing EM, Young TB, Hunt VB, Newton MA, Bram LL, Vaillancourt A, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD. Hematuria home screening: repeat testing results. J Urol. 1995 Jul; 154(1):57-61.
    View in: PubMed
  189. Glazier DB, Bahnson RR, McLeod DG, von Roemeling RW, Messing EM, Ernstoff MS. Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study. J Urol. 1995 Jul; 154(1):66-8.
    View in: PubMed
  190. Tomic S, Warner TF, Messing E, Wilding G. Penile Merkel cell carcinoma. Urology. 1995 Jun; 45(6):1062-5.
    View in: PubMed
  191. Lamm DL, Blumenstein BA, David Crawford E, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, Loehrer P, Barton Grossman H. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. Urol Oncol. 1995 May-Jun; 1(3):119-26.
    View in: PubMed
  192. Messing EM, Young TB, Hunt VB, Gilchrist KW, Newton MA, Bram LL, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995 Mar; 45(3):387-96; discussion 396-7.
    View in: PubMed
  193. Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther M, Fisher HA, Messing E, et al. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res. 1995 Jan; 1(1):57-61.
    View in: PubMed
  194. Jønler M, Ritter MA, Brinkmann R, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis. Urology. 1994 Dec; 44(6):876-82.
    View in: PubMed
  195. Kloth MT, Gee RL, Messing EM, Swaminathan S. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells. Carcinogenesis. 1994 Dec; 15(12):2781-7.
    View in: PubMed
  196. Messing EM, Murphy-Brooks N. Recovery of epidermal growth factor in voided urine of patients with bladder cancer. Urology. 1994 Oct; 44(4):502-6.
    View in: PubMed
  197. Jønler M, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of radical prostatectomy. Br J Urol. 1994 Sep; 74(3):352-8.
    View in: PubMed
  198. Messing EM. Interstitial cystitis. J Urol. 1994 Feb; 151(2):355-6.
    View in: PubMed
  199. Frederickson SM, Messing EM, Reznikoff CA, Swaminathan S. Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells. Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb; 3(1):25-32.
    View in: PubMed
  200. Sollinger HW, Messing EM, Eckhoff DE, Pirsch JD, D'Alessandro AM, Kalayoglu M, Knechtle SJ, Hickey D, Belzer FO. Urological complications in 210 consecutive simultaneous pancreas-kidney transplants with bladder drainage. Ann Surg. 1993 Oct; 218(4):561-8; discussion 568-70.
    View in: PubMed
  201. Waples MJ, Messing EM. Redo retroperitoneal lymphadenectomy for germ cell tumor. Urology. 1993 Jul; 42(1):31-4.
    View in: PubMed
  202. Reznikoff CA, Kao C, Messing EM, Newton M, Swaminathan S. A molecular genetic model of human bladder carcinogenesis. Semin Cancer Biol. 1993 Jun; 4(3):143-52.
    View in: PubMed
  203. Phillips E, Messing EM. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology. 1993 Jan; 41(1):9-15.
    View in: PubMed
  204. Sidransky D, Messing E. Molecular genetics and biochemical mechanisms in bladder cancer. Oncogenes, tumor suppressor genes, and growth factors. Urol Clin North Am. 1992 Nov; 19(4):629-39.
    View in: PubMed
  205. Messing EM. Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors. Semin Surg Oncol. 1992 Sep-Oct; 8(5):285-92.
    View in: PubMed
  206. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol. 1992 Aug; 10(8):1208-17.
    View in: PubMed
  207. Messing EM, Young TB, Hunt VB, Roecker EB, Vaillancourt AM, Hisgen WJ, Greenberg EB, Kuglitsch ME, Wegenke JD. Home screening for hematuria: results of a multiclinic study. J Urol. 1992 Aug; 148(2 Pt 1):289-92.
    View in: PubMed
  208. Pink JC, Messing EM, Reznikoff CA, Bryan GT, Swaminathan S. Correlation between N-acetyltransferase activities in uroepithelia and in vivo acetylator phenotype. Drug Metab Dispos. 1992 Jul-Aug; 20(4):559-65.
    View in: PubMed
  209. Briggs NC, Young TB, Gilchrist KW, Vaillancourt AM, Messing EM. Age as a predictor of an aggressive clinical course for superficial bladder cancer in men. Cancer. 1992 Mar 15; 69(6):1445-51.
    View in: PubMed
  210. Messing EM, Reznikoff CA. Epidermal growth factor and its receptor: markers of--and targets for--chemoprevention of bladder cancer. J Cell Biochem Suppl. 1992; 16I:56-62.
    View in: PubMed
  211. Loprinzi CL, Messing EM. A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer. J Cell Biochem Suppl. 1992; 16I:153-5.
    View in: PubMed
  212. Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Draeger BJ. Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. J Urol. 1991 Dec; 146(6):1631-6.
    View in: PubMed
  213. Edelman GC, Sweet ME, Messing EM, Helgerson RB. Treatment of severe electrical burns of the genitalia and perineum by early excision and grafting. Burns. 1991 Dec; 17(6):506-9.
    View in: PubMed
  214. Messing EM. Interstitial cystitis. N Y State J Med. 1991 Mar; 91(3):91-2.
    View in: PubMed
  215. Dreicer R, Messing EM, Loehrer PJ, Trump DL. Perioperative methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for poor risk transitional cell carcinoma of the bladder: an Eastern Cooperative Oncology Group pilot study. J Urol. 1990 Nov; 144(5):1123-6; discussion 1126-7.
    View in: PubMed
  216. Malec JF, Romsaas EP, Messing EM, Cummings KC, Trump DL. Psychological and mood disturbance associated with the diagnosis and treatment of testis cancer and other malignancies. J Clin Psychol. 1990 Sep; 46(5):551-7.
    View in: PubMed
  217. Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med. 1990 Sep; 32(9):838-45.
    View in: PubMed
  218. Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res. 1990 Apr 15; 50(8):2530-7.
    View in: PubMed
  219. Messing EM, Young TB, Hunt VB, Wehbie JM, Rust P. Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer. 1989 Dec 1; 64(11):2361-7.
    View in: PubMed
  220. Goldrath DE, Messing EM. Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy. J Urol. 1989 Oct; 142(4):1082-4.
    View in: PubMed
  221. Trump DL, Havlin KH, Messing EM, Cummings KB, Lange PH, Jordan VC. High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects. J Clin Oncol. 1989 Aug; 7(8):1093-8.
    View in: PubMed
  222. Busch DB, Bryan GT, Easterling D, Leventhal H, Messing EM, Cummings KB. Follow-up: recontacting subjects in mutagen exposure monitoring studies. IRB. 1988 Sep-Oct; 10(5):9-11.
    View in: PubMed
  223. Messing EM, Hanson P, Reznikoff CA. Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. Cancer Res. 1988 Jan 15; 48(2):357-61.
    View in: PubMed
  224. Messing EM, Hanson P, Ulrich P, Erturk E. Epidermal growth factor--interactions with normal and malignant urothelium: in vivo and in situ studies. J Urol. 1987 Nov; 138(5):1329-35.
    View in: PubMed
  225. Gillespie L, Messing EM. When cystitis is suspected, what's the next step? NAACOG Newsl. 1987 Oct; 14(10):1, 4-6.
    View in: PubMed
  226. Messing EM, Reznikoff CA. Normal and malignant human urothelium: in vitro effects of epidermal growth factor. Cancer Res. 1987 May 1; 47(9):2230-5.
    View in: PubMed
  227. Messing EM, Young TB, Hunt VB, Emoto SE, Wehbie JM. The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J Urol. 1987 May; 137(5):919-22.
    View in: PubMed
  228. Messing EM. The diagnosis of interstitial cystitis. Urology. 1987 Apr; 29(4 Suppl):4-7.
    View in: PubMed
  229. Durzinsky DS, Messing EM, Myerowitz PD, Pellett JR, Wilson MA. Method for assuring accuracy of bone biopsy using technetium 99 bone scan. Cancer. 1987 Feb 15; 59(4):723-5.
    View in: PubMed
  230. Messing EM. Early stage bladder cancer. Wis Med J. 1987 Feb; 86(2):14-7.
    View in: PubMed
  231. Busch DB, Bryan GT, Messing EM, Cummings KB. Recontacting subjects in mutagen exposure monitoring studies. IRB. 1986 Nov-Dec; 8(6):1-4.
    View in: PubMed
  232. Rodriguez PN, Hafez GR, Messing EM. Nonseminomatous germ cell tumor of the testicle: does extensive staging of the primary tumor predict the likelihood of metastatic disease? J Urol. 1986 Sep; 136(3):604-8.
    View in: PubMed
  233. Fisher DT, Messing EM, Bruskewitz RC, Dibbell DG. Use of loop double-lumen drainage system to prevent postoperative urinary diversion leaks. Urology. 1986 Jun; 27(6):553.
    View in: PubMed
  234. Messing EM, Love RR, Kvols LK. Lymphocele after retroperitoneal node dissection for testis tumor. Cancer. 1986 Feb 15; 57(4):871-4.
    View in: PubMed
  235. Messing EM, Dibbell DG, Belzer FO. Bilateral rectus femoris pedicle flaps for detrusor augmentation in the prune belly syndrome. J Urol. 1985 Dec; 134(6):1202-5.
    View in: PubMed
  236. Roach R, Messing E, Starling J. Spontaneous thrombosis of left spermatic vein: report of 2 cases. J Urol. 1985 Aug; 134(2):369-70.
    View in: PubMed
  237. Mohs FE, Snow SN, Messing EM, Kuglitsch ME. Microscopically controlled surgery in the treatment of carcinoma of the penis. J Urol. 1985 Jun; 133(6):961-6.
    View in: PubMed
  238. Messing EM, Bubbers JE, Dekernion JB, Fahey JL. Growth stimulating activity produced by human bladder cancer cells. J Urol. 1984 Dec; 132(6):1230-4.
    View in: PubMed
  239. Schmidt WW, Messing EM, Reznikoff CA. Cultures of normal human urothelial cells from ureters of perfused cadaver transplant kidneys. J Urol. 1984 Dec; 132(6):1262-4.
    View in: PubMed
  240. Messing EM, Bubbers JE, Whitmore KE, deKernion JB, Nestor MS, Fahey JL. Murine hybridoma antibodies against human transitional carcinoma-associated antigens. J Urol. 1984 Jul; 132(1):167-72.
    View in: PubMed
  241. Messing EM, Fahey JL, deKernion JB, Bhuta SM, Bubbers JE. Serum-free medium for the in vitro growth of normal and malignant urinary bladder epithelial cells. Cancer Res. 1982 Jun; 42(6):2392-7.
    View in: PubMed
  242. Messing E, deKernion JB. Adjuvant therapy for genitourinary cancer. Surg Clin North Am. 1981 Dec; 61(6):1331-46.
    View in: PubMed
  243. Messing E, Tarsin M. Antibody coating of bacteria persisting in a ureteral stump 10 years after nephrectomy. J Urol. 1981 Sep; 126(3):406-8.
    View in: PubMed
  244. Messing EM, Henry SC. Stones in orthotopic, non-obstructing ureteroceles. J Urol. 1979 Sep; 122(3):403-4.
    View in: PubMed
  245. Messing EM, Freiha FS. Complication of Clorpactin WCS90 therapy for interstitial cystitis. Urology. 1979 Apr; 13(4):389-92.
    View in: PubMed
  246. Messing EM, Stamey TA. Interstitial cystitis: early diagnosis, pathology, and treatment. Urology. 1978 Oct; 12(4):381-92.
    View in: PubMed
  247. Jahnke RW, Messing EM, Spellman MC. Hypertension and post-traumatic renal arteriovenous fistula: demonstration of unilaterally elevated renin secretion. J Urol. 1976 Nov; 116(5):646-7.
    View in: PubMed
  248. Messing E, Kessler R, Kavaney PB. Renal arteriovenous fistulas. Urology. 1976 Aug; 8(2):101-7.
    View in: PubMed

Visualizations


Messing's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department